Find a Clinical Trial

Showing 41 - 50 of 293 Trials

NRG-GY018: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER

Principal Investigator:

Jason D. Wright, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03914612

Population:

Adult

Phase:

III

We are doing this study because we want to find out if adding a new immunotherapy drug to the usual combination of chemotherapy drugs is better or worse than the usual approach for your endometrial cancer. The usual approach is defined as care most people get for endometrial cancer. Are you Eligible? (Inclusion Criteria) Diagnosis of endometrial cancer Measurable stage III, measurable stage IVA, stage IVB or recurrent endometrial cancer. Must have measurable lesion on CT or MRI scan
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Principal Investigator:

Jason D. Wright, MD

Contact Number:

212-342-5162

NCT Number:

NCT04095364

Population:

Adult

Phase:

III

This study is being done to answer the following question: Can we lower the chance of your ovarian or peritoneal cancer growing or spreading with a hormonal drug used either by itself or by adding it to the usual combination of chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your ovarian or peritoneal cancer. The usual approach is defined as care most people get for ovarian and peritoneal cancer. Are you Eligible? (Inclusion Criteria) must have newly diagnosed, Stage II-IV low-grade serous ovarian cancer...
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Principal Investigator:

Joseph G. Jurcic, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03258931

Population:

Adult

Phase:

III

The purpose of this study is to compare the efficacy of crenolanib versus midostaurin (RYDAPT®) in newly diagnosed acute myeloid leukemia patients with FLT3 mutations. Crenolanib is an investigational product, which means that it has not yet been approved for sale in the United States by the Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Are you between the age ≥ 18 years and ≤ 60 years? (2) Do you have Diagnosis of AML? (3) Do you agree to not participate in another study while on treatment for this study?
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Principal Investigator:

Tony J. Wang, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04114981

Population:

Adult

Phase:

III

The purpose of this study is assess the role of post-operative single fraction stereotactic surgery (SSRS) to the surgical bed after brain metastases resection. This is a Phase III trial comparing post-operative fractionated SRS (FSRS) with single fraction stereotactic radiosurgery (SSRS) in patients with resected brain metastases. In this study, eligible subjects will be randomized to either FSRS or SSRS. Are you Eligible? (Inclusion Criteria) For a subject to be considered for this trial, the subject: 1. Must speak English, Spanish or French. 2. Must not have any prior whole brain radiation...
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Principal Investigator:

Karie Danielle Keera Runcie, MD

Contact Number:

212-342-5162

NCT Number:

NCT02912559

Population:

Adult

Phase:

III

This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body’s immune system to more effectively kill cancer cells in your body. One of the purposes of this study is to determine if giving atezolizumab and the chemotherapy FOLFOX decreases the risk of colon cancer recurrence to a greater degree than does FOLFOX chemotherapy alone. Are you Eligible? (Inclusion Criteria) Are you 18...
SWOG 1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Principal Investigator:

Simon K. Cheng, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04155034

Population:

Adult

Phase:

III

We are doing this study because we want to find out if MRI brain scans alone is better or worse than MRI brain scans plus preventative brain radiation for patients with small lung cancer. The usual approach for patients with small cell lung cancer is prophylactic cranial irradiation. If you decide to take part in this study, you will either receive PCI for two weeks and brain MRIs for two years, or you will just receive brain MRIs for two years. Are you Eligible? (Inclusion Criteria) To be included in this study, you must: have diagnosis of small-cell lung cancer (SCLC) confirmed by pathology...
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (CCTG MA.39)

Principal Investigator:

Eileen Patricia Connolly, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT03488693

Population:

Adult

Phase:

III

The purpose of this study is to compare any good and bad effects of not giving regional radiotherapy to using regional radiotherapy. This study will help researchers learn if not giving regional radiotherapy is just as good as using regional radiotherapy. To be better, the approach of not giving regional radiotherapy should keep your breast cancer from coming back as good as giving regional radiotherapy. There will be about 2140 people taking part in this study. Are you Eligible? (Inclusion Criteria) To be eligible for this study, subjects must: 1. be ≥ 40 years of age. 2. have been...
Targeted (Intra)arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with Sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC)

Principal Investigator:

Susan E. Bates, MD

Contact Number:

212-342-5162

NCT Number:

NCT03257033

Population:

Adult

Phase:

III

The purpose of this research study is to find out whether using a newer method of targeted local delivery of the chemotherapy directly into an artery close to the pancreas tumor after treatment with standard chemotherapy that is delivered by vein is more effective at preventing the tumor from growing as compared with just receiving standard chemotherapy into a vein that goes throughout the body. This study will compare how IA and IV medication affects the time that patients survive and their quality of life. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Histologically or...
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT04457596

Population:

Adult

Phase:

III

This study is being done to answer the following question: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing cancer from returning? This study is being done to find out if this approach is better or worse than the usual approach for breast cancer. The usual approach is defined as care most people get for breast cancer. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Do you have HER2-positive breast cancer and have already received treatment with chemotherapy and anti-HER2 targeted therapies followed by...
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

Principal Investigator:

Eileen Patricia Connolly, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT02364557

Population:

Adult

Phase:

II/III

The purpose of the study is to determine whether ablation, which is the removal or destruction of a tumor (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients improves progression-free survival (PFS) and overall survival (OS). Are you Eligible? (Inclusion Criteria) Metastatic breast cancer confirmed by pathology ≤ 4 metastases seen on standard imaging within 60 days prior to registration when all metastatic disease is located within the following sites: • peripheral lung • osseous (bone) • spine • central lung...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages